Recurrence and Circulating Tumor DNA in Human Papillomavirus-Positive Oropharyngeal Cancer: A Meta-Analysis
Post-treatment ctDNA testing in HPV-positive OPSCC showed 80% sensitivity and 96% specificity for detecting recurrence, with a negative test yielding a 97.7% NPV at a 9.7% recurrence prevalence. A positive result carried 130-fold higher odds of recurrence, though inconsistent protocols currently limit clinical implementation.